Clinical Trial Update: Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on VG801 for Stargardt disease due to ABCA4 mutations, reporting safety assessments and preliminary efficacy signals from Phase 1/2 while …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• VG801

Snippet

Sponsor: VeonGen Therapeutics GmbH | Conditions: Retinal Dystrophy Due to Biallelic ABCA4 Mutations, Stargardt Disease 1 | Phase 1, Phase 2 | Status: RECRUITING